Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2011

01-12-2011 | Original Paper

Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy

Authors: Mohammad R. Noori-Daloii, Majid Momeny, Mehdi Yousefi, Forough Golsaz Shirazi, Mehdi Yaseri, Nasrin Motamed, Nazanin Kazemialiakbar, Saeed Hashemi

Published in: Medical Oncology | Issue 4/2011

Login to get access

Abstract

The aim of the present study is to evaluate the effects of quercetin, a dietary flavonoid, on human prostate adenocarcinoma PC-3 cells. Lactate dehydrogenase (LDH) release, microculture tetrazolium test (MTT assay) and real-time PCR array were employed to evaluate the effects of quercetin on cell cytotoxicity, cell proliferation and expression of various genes in PC-3 cell line. Quercetin inhibited cell proliferation and modulated the expression of genes involved in DNA repair, matrix degradation and tumor invasion, angiogenesis, apoptosis, cell cycle, metabolism and glycolysis. No cytotoxicity of quercetin on PC-3 cells was observed. Taken together, as shown by the issues of the current study, the manifold inhibitory effects of quercetin on PC-3 cells may introduce quercetin as an efficacious anticancer agent in order to be used in the future nutritional transcriptomic investigations and multi-target therapy to overcome the therapeutic impediments against prostate cancer.
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:67–125.CrossRef
2.
Nelson WG, De Marzo AM, Isaacs WB. Mechanisms of disease: prostate cancer. New Eng J Med. 2003;349:366–81.PubMedCrossRef
3.
Deutsch E, Maggiorella L, Eschwege P, Bourhis J, Soria J, et al. Environmental, genetic, and molecular features of prostate cancer. Lancet Oncol. 2004;5:303–13.PubMedCrossRef
4.
5.
6.
Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol. 1991;30:133–40.PubMedCrossRef
7.
Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 1991;63:963–9.PubMedCrossRef
8.
Neuhouser ML. Dietary flavonoids and cancer risk: evidence from human population studies. Nutr Cancer. 2004;50:1–7.PubMedCrossRef
9.
10.
Adlercreutz H, Mazur W, Bartels P, Elomaa VV, Watanabe S, et al. Phytoestrogens and prostate disease. J Nutr. 2000;130:658S–9S.PubMed
11.
Lampe J. Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr. 2003;133:956S–64S.PubMed
12.
Aherne SA, O’Brien NM. Dietary flavonols: chemistry, food content, and metabolism. Nutrition. 2002;18:75–81.PubMedCrossRef
13.
Hertog MG, Hollman PC, Katan MB. Content of potentially anticarcinogenic flavonoids of 28 vegetables and 9 fruits commonly consumed in The Netherlands. J Agric Food Chem. 1992;40:2379–83.CrossRef
14.
Haddad AQ, Venkateswaran V, Viswanathan L, Teahan SJ, Fleshner NE, et al. Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell lines. Prostate Cancer Prostatic Dis. 2006;9:68–76.PubMedCrossRef
15.
Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr. 2002;76:560–8.PubMed
16.
Garcia-Closas R, Agudo A, Gonzalez CA, Riboli E. Intake of specific carotenoids and flavonoids and the risk of lung cancer in women in Barcelona, Spain. Nutr Cancer. 1998;32:154–8.PubMedCrossRef
17.
De Stefani E, Boffetta P, Deneo-Pellegrini H, Mendilaharsu M, Carzoglio JC, et al. Dietary antioxidants and lung cancer risk: a case-control study in Uruguay. Nutr Cancer. 1999;34:100–10.PubMedCrossRef
18.
Garcia R, Gonzalez CA, Agudo A, Riboli E. High intake of specific carotenoids and flavonoids does not reduce the risk of bladder cancer. Nutr Cancer. 1999;35:212–4.PubMedCrossRef
19.
Garcia-Closas R, Gonzalez CA, Agudo A, Riboli E. Intake of specific carotenoids and flavonoids and the risk of gastric cancer in Spain. Cancer Causes Control. 1999;10:71–5.PubMedCrossRef
20.
Le Marchand L, Murphy SP, Hankin JH, Wilkens LR, Kolonel LN. Intake of flavonoids and lung cancer. JNCI. 2000;92:154–60.PubMedCrossRef
21.
Peterson J, Lagiou P, Samoli E, Lagiou A, Katsouyanni K, et al. Flavonoid intake and breast cancer risk: a case-control study in Greece. Br J Cancer. 2003;89:1255–9.PubMedCrossRef
22.
Xing N, Chen Y, Mitchell SH, Young CY. Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 2001;22:409–14.PubMedCrossRef
23.
Nair HK, Rao KV, Aalinkeel R, Mahajan S, Chawda R, et al. Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory genes. Clin Diagn Lab Immunol. 2004;11:63–9.PubMed
24.
Vijayababu MR, Kanagaraj P, Arunkumar A, Ilangovan R, Dharmarajan A, et al. Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: a possible mediation by IGFBP-3. Oncol Res. 2006;16:67–74.PubMed
25.
Vijayababu MR, Arunkumar A, Kanagaraj P, Venkataraman P, Krishnamoorthy G, et al. Quercetin downregulates matrix metalloproteinases 2 and 9 proteins expression in prostate cancer cells (PC-3). Mol Cell Biochem. 2006;287:109–16.PubMedCrossRef
26.
Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem. 2005;280:5636–45.PubMedCrossRef
27.
Shenouda NS, Zhou C, Browning JD, Ansell PJ, Sakla MS, et al. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer. 2004;49:200–8.PubMedCrossRef
28.
Morris J, Pramanik R, Zhang X, Carey A, Ragavan N, et al. Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity. Cancer Lett. 2006;239:111–22.PubMedCrossRef
29.
Mutch DM, Wahli W, Williamson G. Nutrigenomics and nutrigenetics. The emerging faces of nutrition. FASEB J. 2005;19:1602–16.PubMedCrossRef
30.
Muller M, Kersten S. Nutrigenomics: goals and strategies. Nat Rev Cancer. 2003;4:315–22.CrossRef
31.
Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:180–92.CrossRef
32.
Hakomi S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996;56:5309–18.
33.
Vlodavski L, Goldshmidta O, Zchariaa E, Metzgerb S, Chajek-Shaulb T, et al. Molecular properties and involvement of heparanase in cancer progression and normal development. Biochimie. 2001;83:831–9.CrossRef
34.
35.
Liu YY, Han T, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001;15:719–30.PubMedCrossRef
36.
Payne SG, Milstien S, Spiegel S. Sphingosine-1-phosphate: dual messenger functions. FEBS Lett. 2003;531:54–7.CrossRef
37.
Santana P, Pen LA, Haimovitz-Friedman A, Martin S, Green D, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 1996;86:189–99.PubMedCrossRef
38.
Brusselmans K, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl-CoA carboxylase-α gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res. 2005;65:6719–25.PubMedCrossRef
39.
Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, et al. The isopeptidase USP2a protects human prostate cancer from apoptosis. Cancer Res. 2006;66:8625–32.PubMedCrossRef
40.
Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.PubMedCrossRef
41.
Hatzivassiliou G, Zhao F, Bauer D, Andreadis C, Shaw A, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005;8:311–21.PubMedCrossRef
42.
Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763–77.PubMedCrossRef
43.
Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 2005;65:2378–86.PubMedCrossRef
44.
Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005;24:2474–82.PubMedCrossRef
45.
O’Kane H, Watson C, Johnston S, Petak I, William R, et al. Targeting death receptors in bladder, prostate and renal cancer. J Urol. 2006;175:432–8.PubMedCrossRef
46.
Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis. 2004;8:29–37.CrossRef
47.
Abe M, Manola JB, Oh WK, Parslow DL, George DJ, et al. Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer. 2004;3:49–53.PubMed
48.
Isaacs J, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 2003;3:213–7.PubMedCrossRef
49.
Xia G, Kumar SR, Masood R, Zhu S, Reddy R, et al. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005;65:4623–32.PubMedCrossRef
50.
Nicholson B, Teodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem. 2003;91:125–50.CrossRef
51.
Lawrence YR, Dicker AP. Hypoxia in prostate cancer: observation to intervention. Lancet Oncol. 2008;9:308–9.PubMedCrossRef
52.
Morey SR, Smiraglia DJ, James SR, Yu J, Moser MT. DNA methylation pathway alterations in an autochthonous murine model of prostate cancer. Cancer Res. 2006;66:11659–67.PubMedCrossRef
53.
Halkidou K. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Euro Urol. 2005;45:382–9.CrossRef
54.
Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, et al. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832–7.PubMed
55.
Yu G, Tseng GC, Yu YP, Gavel T, Nelson J. CSR1 suppresses tumor growth and metastasis of prostate cancer. Am J Pathol. 2006;168:597–607.PubMedCrossRef
56.
Jaeger EB, Samant RS, Rinker-Schaeffer CW. Metastasis suppression in prostate cancer. Cancer Metastasis Rev. 2004;20:279–86.CrossRef
57.
Khodavirdi AC, Song Z, Yang S, Zhong C, Wang S, et al. Increased expression of osteopontin contributes to the progression of prostate cancer. Cancer Res. 2006;66:883–8.PubMedCrossRef
58.
Chesire DR, Isaacs WB. Beta-catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer. 2003;10:537–60.PubMedCrossRef
59.
Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer. 2005;5:786–95.PubMedCrossRef
60.
Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000;6:1891–5.PubMed
61.
Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res. 2001;29:25–8.CrossRef
62.
Lloyd MD, Darley DJ, Wierzbicki AS, Threadgill MD. Alpha-methylacyl-CoA racemase—an ‘obscure’ metabolic enzyme takes centre stage. FEBS J. 2008;44:1089–102.CrossRef
63.
Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem. 1998;44:705–23.PubMed
64.
Wei RR, Al-Bassam J, Harrison SC. The Ndc80/HEC1 complex is a contact point for kinetochore-microtubule attachment. Nat Struct Mol Biol. 2007;14:54–9.PubMedCrossRef
65.
Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumor suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2007;8:83–93.CrossRef
66.
Floryk D, Tollaksen SL, Giometti CS, Huberman E. Differentiation of human prostate cancer PC-3 cells induced by inhibitors of inosine 5′-monophosphate dehydrogenase. Cancer Res. 2004;64:9049–56.PubMedCrossRef
67.
Hughes C, Murphy A, Martin C, Sheils O, O’Leary J. Molecular pathology of prostate cancer. J Clin Pathol. 2005;58:673–84.PubMedCrossRef
68.
Meyera H, Ahrens-Fathb I, Sommera A, Haendler B. Novel molecular aspects of prostate carcinogenesis. Biomed Pharmacother. 2004;58:10–6.CrossRef
69.
Ren W, Qiao Z, Wang H, Zhu L, Zhang L. Flavonoids: promising anticancer agents. Med Res Rev. 2003;23:519–34.PubMedCrossRef
70.
Kioka N, Hosokawa N, Komano T, Hirayoshi K, Nagata K, et al. Quercetin, a bioflavonoid, inhibits the increase of human multidrug resistance gene (MDR1) expression caused by arsenite. FEBS Lett. 1992;301:307–9.PubMedCrossRef
71.
Igura K, Ohta T, Kuroda Y, Kaji K. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett. 2001;171:11–6.PubMedCrossRef
72.
Romero I, Páez A, Ferruelo A, Luján M, Berenguer A. Polyphenols in red wine inhibit the proliferation and induce apoptosis of LNCaP cells. BJU Inter. 2002;89:950–4.CrossRef
73.
Kobayashi T, Nakata T, Kuzumaki T. Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett. 2002;176:17–23.PubMedCrossRef
74.
Lambert JD, Hong J, Yang G, Liao J, Yang CS. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr. 2005;81:284S–91S.PubMed
75.
Murota K, Hotta A, Ido H, Kawai Y, Moon J, et al. Antioxidant capacity of albumin-bound quercetin metabolites after onion consumption in humans. J Med Invest. 2007;54:370–4.PubMedCrossRef
76.
Dihal A, Woutersen R, Ommen B, Rietjens I, Stierum R. Modulatory effects of quercetin on proliferation and differentiation of the human colorectal cell line Caco-2. Cancer Lett. 2006;238:248–59.PubMedCrossRef
77.
Okamoto T. Safety of quercetin for clinical application (review). Int J Mol Med. 2005;16:275–8.PubMed
78.
Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, et al. ABT-888, an orally active poly(ADP-Ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007;13:2728–37.PubMedCrossRef
79.
Kelley MR, Fishel ML. DNA repair proteins as molecular targets for cancer therapeutics. Anti-Cancer Agents Med Chem. 2008;8:417–25.
80.
Blunt T, Finnie NJ, Taccioli GE, Smith GC, Demengeot J, et al. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation. Cell. 1995;80:813–23.PubMedCrossRef
81.
Fuster MM, Esko JD. The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat Cancer Rev. 2005;5:526–42.CrossRef
82.
Yoshimura M, Ihara Y, Matsuzawa Y, Taniguchi N. Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis. J Biol Chem. 1996;271:13811–5.PubMedCrossRef
83.
Adatia R, Albini A, Carlone S, Giunciuglio D, Benelli R, et al. Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA. Ann Oncol. 1997;8:1257–61.PubMedCrossRef
84.
Zcharia E, Metzger S, Chajek-Shaul T, Friedmann Y, Pappo O, et al. Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis. J Mammary Gland Biol Neoplasia. 2001;6:311–22.PubMedCrossRef
85.
Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004;4:604–16.PubMedCrossRef
86.
Hannun YA. Functions of ceramide in coordinating cellular responses to stress. Science. 1996;274:1855–9.PubMedCrossRef
87.
Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 2005;24:6314–22.PubMedCrossRef
88.
Graner E, Tang D, Rossi S, Baron A, Migita T, et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell. 2004;5:253–61.PubMedCrossRef
89.
Chen L, Pankiewicz KW. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Dev. 2007;10:403–12.
90.
Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007;12:34–42.PubMedCrossRef
91.
Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8:61–70.PubMedCrossRef
92.
Davis CD, Milner J. Frontiers in nutrigenomics, proteomics, metabolomics and cancer prevention. Mut Res. 2004;551:51–64.CrossRef
Metadata
Title
Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy
Authors
Mohammad R. Noori-Daloii
Majid Momeny
Mehdi Yousefi
Forough Golsaz Shirazi
Mehdi Yaseri
Nasrin Motamed
Nazanin Kazemialiakbar
Saeed Hashemi
Publication date
01-12-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9603-3

Other articles of this Issue 4/2011

Medical Oncology 4/2011 Go to the issue

Original Paper

More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin

Original Paper

Malignant transformation of foveolar hyperplastic polyp of the stomach: a histopathological study

Original Paper

Metastatic factors for Krukenberg tumor: a clinical study on 102 cases

Original Paper

Bilateral ocular involvement as a presentation of Waldenström’s macroglobulinemia

Original paper

Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy

Original Paper

Prognosis of small-cell lung cancer since the introduction of amrubicin
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits